Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets

References

• Agrawal M, Spencer EA, Colombel J-F, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161(1):47–24. doi:10.1053/j.gastro.2021.04.063.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0.
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607. doi:10.1136/gut.2010.224154.
   PubMed Web of Science ®Google Scholar
• Chang JT, Longo DL. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652–2664. doi:10.1056/NEJMra2002697.
   PubMed Web of Science ®Google Scholar
• Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastro Hepat. 2017;14(10):573–584. doi:10.1038/nrgastro.2017.88.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Le Berre C, Ingelfinger JR, Ingelfinger JR. Newer Biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med. 2021;385(14):1302–1315. doi:10.1056/NEJMra1907607.
   PubMed Web of Science ®Google Scholar
• Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, et al. The pathogenesis of Extraintestinal manifestations: implications for IBD Research, Diagnosis, and therapy. J Crohn’s Colitis. 2019;13(5):541–554. doi:10.1093/ecco-jcc/jjy191.
   Google Scholar
• Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de AM, Boberg KM, Burisch J, De Vos M, De Vries A-M, Dick AD, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn’s Colitis. 2016;10(3):239–254. doi:10.1093/ecco-jcc/jjv213.
   Google Scholar
• Bandinelli F, Manetti M, Ibba-Manneschi L. Occult spondyloarthritis in inflammatory bowel disease. Clin Rheumatol. 2016;35(2):281–289. doi:10.1007/s10067-015-3074-z.
   PubMed Web of Science ®Google Scholar
• Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, van Bodegraven AA, de Jong DJ, van der Woude CJ, Romberg-Camps MJL, et al. Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohn’s Colitis. 2016;10(4):455–461. doi:10.1093/ecco-jcc/jjv238.
   Google Scholar
• Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, Cannizzaro A, Sireci G, De Leo G, Alessandro R, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747. doi:10.1136/annrheumdis-2014-206323.
   PubMed Web of Science ®Google Scholar
• Schwartzman M, Ermann J, Kuhn KA, Schwartzman S, Weisman MH. Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs. RMD Open. 2022;8(1):e001777. doi:10.1136/rmdopen-2021-001777.
   PubMed Web of Science ®Google Scholar
• Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroentero. 2006;12(30):4819–4831. doi:10.3748/wjg.v12.i30.4819.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–1992. doi:10.1097/MIB.0000000000000392.
   PubMed Web of Science ®Google Scholar
• Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021;70(4):796–802. doi:10.1136/gutjnl-2020-322129.
   PubMed Web of Science ®Google Scholar
• Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387–391. doi:10.1136/gut.42.3.387.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional Association between psoriasis and inflammatory bowel disease—A systematic review and meta-analysis. J Crohn’s Colitis. 2020;14(3):351–360. doi:10.1093/ecco-jcc/jjz152.
   Google Scholar
• Jansen FM, Vavricka SR, den Broeder AA, de Jong EM, Hoentjen F, van Dop WA. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. United Eur Gastroenterol J. 2020;8(9):1031–1044. doi:10.1177/2050640620958902.
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of crohnʼs disease and ulcerative colitis: a study of 700 patients. Med. 1976;55(5):401–412. doi:10.1097/00005792-197609000-00004.
   PubMed Web of Science ®Google Scholar
• Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, Aractingi S, Khosrotehrani K. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Med. 2008;87(5):281–293. doi:10.1097/MD.0b013e318187cc9c.
   PubMed Web of Science ®Google Scholar
• Pérez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M. Erythema nodosum: a practical approach and diagnostic algorithm. Am J Clin Dermatol. 2021;22(3):367–378. doi:10.1007/s40257-021-00592-w.
   PubMed Web of Science ®Google Scholar
• Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372. doi:10.1007/s40257-017-0251-7.
   PubMed Web of Science ®Google Scholar
• States V, O’Brien S, Rai JP, Roberts HL, Paas M, Feagins K, Pierce EJ, Baumgartner RN, Galandiuk S. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2020;65(9):2675–2685. doi:10.1007/s10620-019-05999-4.
   PubMed Web of Science ®Google Scholar
• Li JX, Chiang CC, Chen SN, Lin JM, Tsai YY. The prevalence of ocular extra-intestinal manifestations in adults inflammatory bowel disease: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(23):15683. doi:10.3390/ijerph192315683.
   PubMed Web of Science ®Google Scholar
• Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72(18):2333–2349. doi:10.2165/11638120-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Shah J, Shah A, Hassman L, Gutierrez A. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(11):1832–1838. doi:10.1093/ibd/izaa359.
   PubMed Web of Science ®Google Scholar
• Troncoso LL, Biancardi AL, de Moraes HV Jr., Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroentero. 2017;23(32):5836–5848. doi:10.3748/wjg.v23.i32.5836.
   PubMed Web of Science ®Google Scholar
• Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Gastroenterology. 2021;161(6):1865–1877. doi:10.1053/j.gastro.2021.08.032.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao X, Zhou J, Chen S, Zhang J, Zhang Y, Chen B, Yang J. Increased risks of dental caries and periodontal disease in Chinese patients with inflammatory bowel disease. Int Dent J. 2020;70(3):227–236. doi:10.1111/idj.12542.
   PubMed Web of Science ®Google Scholar
• Chau SF, Lee CY, Huang JY, Chou MC, Chen HC, Yang SF. The existence of periodontal disease and subsequent ocular diseases: a population-based cohort study. Medicina (Kaunas, Lithuania). 2020;56(11):621. doi:10.3390/medicina56110621.
   PubMed Web of Science ®Google Scholar
• Madsen GR, Bertl K, Pandis N, Stavropoulos A, Burisch J. The impact of periodontitis on inflammatory bowel disease activity. Inflamm Bowel Dis. 2023;29(3):396–404. doi:10.1093/ibd/izac090.
   PubMed Web of Science ®Google Scholar
• Kwon T, Lamster IB, Levin L. Current Concepts in the management of periodontitis. Int Dent J. 2021;71(6):462–476. doi:10.1111/idj.12630.
   PubMed Web of Science ®Google Scholar
• Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–1132. doi:10.1053/j.gastro.2021.07.042.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz VM, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis. 2015;21(8):1794–1800. doi:10.1097/MIB.0000000000000429.
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Egeberg A. Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark. Clin Gastroenterol Hepatol. 2019;17(13):2704–12.e3. doi:10.1016/j.cgh.2019.03.040.
   PubMed Web of Science ®Google Scholar
• Ferretti F, Monico MC, Cannatelli R, Carmagnola S, Lenti MV, Di Sabatino A, Conforti F, Pastorelli L, Caprioli F, Bezzio C, et al. The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: a multicenter study. Front Med. 2022;9:933357. doi:10.3389/fmed.2022.933357.
   Web of Science ®Google Scholar
• Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut. 1996;38(5):738–741. doi:10.1136/gut.38.5.738.
   PubMed Web of Science ®Google Scholar
• Dahal RH, Kim S, Kim YK, Kim ES, Kim J. Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis. Front Microbiol. 2023;14:1174832. doi:10.3389/fmicb.2023.1174832.
   PubMed Web of Science ®Google Scholar
• Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, Flint HJ, Louis P. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J. 2014;8(6):1323–1335. doi:10.1038/ismej.2014.14.
   PubMed Web of Science ®Google Scholar
• Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin THJ. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010;105(11):2420–2428. doi:10.1038/ajg.2010.281.
   PubMed Web of Science ®Google Scholar
• Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, Furet J-P, Sokol H. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76(9):1614–1622. doi:10.1136/annrheumdis-2016-211064.
   PubMed Web of Science ®Google Scholar
• Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ, Clardy J. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci U S A. 2019;116(26):12672–12677. doi:10.1073/pnas.1904099116.
   PubMed Web of Science ®Google Scholar
• Dorofeyev AE, Vasilenko IV, Rassokhina OA. Joint extraintestinal manifestations in ulcerative colitis. Dig Dis (Basel, Switzerland). 2009;27(4):502–510. doi:10.1159/000233289.
   PubMed Web of Science ®Google Scholar
• Lee IA, Kim DH. Klebsiella pneumoniae increases the risk of inflammation and colitis in a murine model of intestinal bowel disease. Scand J Gastroenterol. 2011;46(6):684–693. doi:10.3109/00365521.2011.560678.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, Alessandro R, Luchetti MM, Milling S, Saieva L, Cypers H, Stampone T, Di Benedetto P, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123–1132. doi:10.1136/annrheumdis-2016-210000.
   PubMed Web of Science ®Google Scholar
• Cardoneanu A, Cozma S, Rezus C, Petrariu F, Burlui AM, Rezus E. Characteristics of the intestinal microbiome in ankylosing spondylitis. Exp Ther Med. 2021;22(1):676. doi:10.3892/etm.2021.10108.
   PubMed Web of Science ®Google Scholar
• El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, Catassi C, Fasano A. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002;123(5):1607–1615. doi:10.1053/gast.2002.36578.
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song S, Yassour M, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host & Microbe. 2014;15(3):382–392. doi:10.1016/j.chom.2014.02.005.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275–1283. doi:10.1136/gutjnl-2013-304833.
   PubMed Web of Science ®Google Scholar
• Min HK, Na HS, Jhun J, Lee SY, Choi SS, Park GE, Lee JS, Um IG, Lee SY, Seo H, et al. Identification of gut dysbiosis in axial spondyloarthritis patients and improvement of experimental ankylosing spondyloarthritis by microbiome-derived butyrate with immune-modulating function. Front Immunol. 2023;14:1096565. doi:10.3389/fimmu.2023.1096565.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet J-P, Corthier G, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736. doi:10.1073/pnas.0804812105.
   PubMed Web of Science ®Google Scholar
• Schade L, Mesa D, Faria AR, Santamaria JR, Xavier CA, Ribeiro D, Hajar FN, Azevedo VF. The gut microbiota profile in psoriasis: a Brazilian case-control study. Lett Appl Microbiol. 2022;74(4):498–504. doi:10.1111/lam.13630.
   PubMed Web of Science ®Google Scholar
• Verma R, Verma AK, Ahuja V, Paul J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J Clin Microbiol. 2010;48(11):4279–4282. doi:10.1128/JCM.01360-10.
   PubMed Web of Science ®Google Scholar
• Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–955. doi:10.1016/j.jhep.2013.01.003.
   PubMed Web of Science ®Google Scholar
• Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107–113. doi:10.1038/nm.4236.
   PubMed Web of Science ®Google Scholar
• Ansaldo E, Slayden LC, Ching KL, Koch MA, Wolf NK, Plichta DR, Brown EM, Graham DB, Xavier RJ, Moon JJ, et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Sci. 2019;364(6446):1179–1184. doi:10.1126/science.aaw7479.
   PubMed Web of Science ®Google Scholar
• Eppinga H, Sperna WCJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, Konstantinov SR. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in Hidradenitis Suppurativa. J Crohn’s Colitis. 2016;10(9):1067–1075. doi:10.1093/ecco-jcc/jjw070.
   Google Scholar
• Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66(6):1039–1048. doi:10.1136/gutjnl-2015-310746.
   PubMed Web of Science ®Google Scholar
• Eppinga H, Thio HB, Schreurs MWJ, Blakaj B, Tahitu RI, Konstantinov SR, Peppelenbosch MP, Fuhler GM. Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF). PloS One. 2017;12(5):e0176955. doi:10.1371/journal.pone.0176955.
   PubMed Web of Science ®Google Scholar
• Sivignon A, de Vallée A, Barnich N, Denizot J, Darcha C, Pignède G, Vandekerckove P, Darfeuille-Michaud A. Saccharomyces cerevisiae CNCM I-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model Mimicking Crohnʼs disease. Inflamm Bowel Dis. 2015;21(2):276–286. doi:10.1097/MIB.0000000000000280.
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen Z, Xu C, Kan S, Chen D. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease. Nutrients. 2022;14(23):14. doi:10.3390/nu14235140.
   Web of Science ®Google Scholar
• Kalyana CS, Jayasudha R, Sai PG, Ali MH, Sharma S, Tyagi M, Shivaji S. Dysbiosis in the gut bacterial microbiome of patients with uveitis, an inflammatory disease of the eye. Indian J Microbiol. 2018;58(4):457–469. doi:10.1007/s12088-018-0746-9.
   PubMed Web of Science ®Google Scholar
• Pan M, Barua N, Ip M. Mucin-degrading gut commensals isolated from healthy faecal donor suppress intestinal epithelial inflammation and regulate tight junction barrier function. Front Immunol. 2022;13:1021094. doi:10.3389/fimmu.2022.1021094.
   PubMed Web of Science ®Google Scholar
• Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, Drastich P, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroentero. 2017;23(25):4548–4558. doi:10.3748/wjg.v23.i25.4548.
   PubMed Web of Science ®Google Scholar
• Steck N, Hoffmann M, Sava IG, Kim SC, Hahne H, Tonkonogy SL, Mair K, Krueger D, Pruteanu M, Shanahan F, et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology. 2011;141(3):959–971. doi:10.1053/j.gastro.2011.05.035.
   PubMed Web of Science ®Google Scholar
• Liwinski T, Zenouzi R, John C, Ehlken H, Rühlemann MC, Bang C, Groth S, Lieb W, Kantowski M, Andersen N, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut. 2020;69(4):665–672. doi:10.1136/gutjnl-2019-318416.
   PubMed Web of Science ®Google Scholar
• Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu P-S, Taniki N, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat microbiol. 2019;4(3):492–503. doi:10.1038/s41564-018-0333-1.
   PubMed Web of Science ®Google Scholar
• Lemoinne S, Kemgang A, Ben BK, Straube M, Jegou S, Corpechot C, Chazouillères O, Housset C, Sokol H. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2020;69(1):92–102. doi:10.1136/gutjnl-2018-317791.
   PubMed Web of Science ®Google Scholar
• Wu L, Han J, Nie JY, Deng T, Li C, Fang C, Xie W-Z, Wang S-Y, Zeng X-T. Alterations and correlations of gut microbiota and fecal metabolome characteristics in experimental periodontitis rats. Front Microbiol. 2022;13:865191. doi:10.3389/fmicb.2022.865191.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, Scharl M, Schoepfer AM, Rogler G, Prinz Vavricka MB, Terracciano L, et al. Expression patterns of TNFα, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease. J Crohn’s Colitis. 2018;12(3):347–354. doi:10.1093/ecco-jcc/jjx158.
   Google Scholar
• Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatol. 2001;33(5):1065–1072. doi:10.1053/jhep.2001.24231.
   PubMed Web of Science ®Google Scholar
• Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22. doi:10.1038/s41572-020-0156-2.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi:10.1038/s41572-020-0205-x.
   PubMed Web of Science ®Google Scholar
• Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, et al. Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence. Gut. 2016;65:225–237. doi:10.1136/gutjnl-2015-309333.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359–2364. doi:10.1084/jem.180.6.2359.
   PubMed Web of Science ®Google Scholar
• Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, Chen J, Kielczewski JL, Silver PB, Jittayasothorn Y, Chan C-C, Yamane H, Honda K, et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity. 2015;43(2):343–353. doi:10.1016/j.immuni.2015.07.014.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516–1526. doi:10.1136/gutjnl-2019-318427.
   PubMed Web of Science ®Google Scholar
• Yu LC. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 2018;25(1):79. doi:10.1186/s12929-018-0483-8.
   PubMedGoogle Scholar
• Tailford LE, Crost EH, Kavanaugh D, Juge N. Mucin glycan foraging in the human gut microbiome. Front Genet. 2015;6:81. doi:10.3389/fgene.2015.00081.
   PubMed Web of Science ®Google Scholar
• Sikora M, Stec A, Chrabaszcz M, Waskiel-Burnat A, Zaremba M, Olszewska M, Rudnicka L. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J Clin Med. 2019;8(7):1021. doi:10.3390/jcm8071021.
   PubMed Web of Science ®Google Scholar
• Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak A. Alterations of the skin and gut microbiome in Psoriasis and Psoriatic arthritis. Int J Mol Sci. 2021;22(8):22. doi:10.3390/ijms22083998.
   Web of Science ®Google Scholar
• Liu S, Zhao W, Lan P, Mou X. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell. 2021;12(5):331–345. doi:10.1007/s13238-020-00745-3.
   PubMed Web of Science ®Google Scholar
• Parthasarathy R, Santiago F, McCluskey P, Kaakoush NO, Tedla N, Wakefield D. The microbiome in HLA-B27-associated disease: implications for acute anterior uveitis and recommendations for future studies. Trends Microbiol. 2022;31(2):142–158. doi:10.1016/j.tim.2022.08.008.
   PubMed Web of Science ®Google Scholar
• Janowitz C, Nakamura YK, Metea C, Gligor A, Yu W, Karstens L, Rosenbaum JT, Asquith M, Lin P. Disruption of intestinal homeostasis and intestinal microbiota during experimental autoimmune uveitis. Invest Ophthalmol Visual Sci. 2019;60(1):420–429. doi:10.1167/iovs.18-24813.
   PubMed Web of Science ®Google Scholar
• Jia X, Jia L, Mo L, Yuan S, Zheng X, He J, Chen V, Guo Q, Zheng L, Yuan Q, et al. Berberine Ameliorates periodontal bone loss by regulating gut microbiota. J Dent Res. 2019;98(1):107–116. doi:10.1177/0022034518797275.
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Claudepierre P. Trafficking of antigens from gut to sacroiliac joints and spine in reactive arthritis and spondyloarthropathies: Mainly through lymphatics? Joint Bone Spine. 2016;83(5):485–490. doi:10.1016/j.jbspin.2015.10.015.
   PubMed Web of Science ®Google Scholar
• Ramírez-Boscá A, Navarro-López V, Martínez-Andrés A, Such J, Francés R, Horga DLPJ, Asín-Llorca M. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151(6):670–671. doi:10.1001/jamadermatol.2014.5585.
   PubMed Web of Science ®Google Scholar
• Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M, Veys EM, De Keyser F. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol. 2002;196(3):343–350. doi:10.1002/path.1044.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. World J Gastroentero. 2019;25(18):2162–2176. doi:10.3748/wjg.v25.i18.2162.
   PubMed Web of Science ®Google Scholar
• Lamps LW, Madhusudhan KT, Havens JM, Greenson JK, Bronner MP, Chiles MC, Dean, P J., Scott, M A. Pathogenic Yersinia DNA is detected in bowel and mesenteric lymph nodes from patients with Crohn’s disease. The American Journal Of Surgical Pathology. 2003;27(2):220–227. doi:10.1097/00000478-200302000-00011.
   PubMed Web of Science ®Google Scholar
• Luchetti MM, Ciccia F, Avellini C, Benfaremo D, Rizzo A, Spadoni T, Svegliati S, Marzioni D, Santinelli A, Costantini A, et al. Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis. Rheumatology (Oxford). 2021;60(1):92–102. doi:10.1093/rheumatology/keaa164.
   PubMed Web of Science ®Google Scholar
• Wells A, Pararajasegaram G, Baldwin M, Yang CH, Hammer M, Fox A. Uveitis and arthritis induced by systemic injection of streptococcal cell walls. Invest Ophthalmol Visual Sci. 1986;27:921–925.
   PubMed Web of Science ®Google Scholar
• Wohlgemuth S, Keller S, Kertscher R, Stadion M, Haller D, Kisling S, Jahreis G, Blaut M, Loh G. Intestinal steroid profiles and microbiota composition in colitic mice. Gut Microbes. 2011;2(3):159–166. doi:10.4161/gmic.2.3.16104.
   PubMed Web of Science ®Google Scholar
• Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, Kiguchi Y, Yasuma K, Watanabe E, Tanoue T, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Sci. 2017;358(6361):359–365. doi:10.1126/science.aan4526.
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG 3rd, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell. 2020;182(2):447–62.e14. doi:10.1016/j.cell.2020.05.048.
   PubMed Web of Science ®Google Scholar
• Fantini MC, Pallone F, Monteleone G. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroentero. 2009;15(20):2472–2478. doi:10.3748/wjg.15.2472.
   PubMed Web of Science ®Google Scholar
• Scofield RH, Kurien B, Gross T, Warren WL, Harley JB, Scofield RH, Harley JB, Scofield RH, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet. 1995;345(8964):1542–1544. doi:10.1016/S0140-6736(95)91089-1.
   PubMed Web of Science ®Google Scholar
• Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, López de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem. 2002;277(40):37573–37581. doi:10.1074/jbc.M205470200.
   PubMed Web of Science ®Google Scholar
• Orda R, Samra Z, Levy Y, Shperber Y, Scapa E. Chlamydia trachomatis and inflammatory bowel disease–a coincidence? J R Soc Med. 1990;83(1):15–17. doi:10.1177/014107689008300108.
   PubMed Web of Science ®Google Scholar
• Schwimmbeck PL, Yu DT, Oldstone MB. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter’s syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med. 1987;166(1):173–181. doi:10.1084/jem.166.1.173.
   PubMed Web of Science ®Google Scholar
• Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, Binder A, Bansal S, Ebringer A. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett. 1995;369(2–3):243–248. doi:10.1016/0014-5793(95)00760-7.
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastro Hepat. 2020;17(4):223–237. doi:10.1038/s41575-019-0258-z.
   PubMed Web of Science ®Google Scholar
• Heinken A, Ravcheev DA, Baldini F, Heirendt L, Fleming RMT, Thiele I. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome. 2019;7(1):75. doi:10.1186/s40168-019-0689-3.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. Bile acids: natural ligands for an orphan nuclear receptor. Sci. 1999;284(5418):1365–1368. doi:10.1126/science.284.5418.1365.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435–9440. doi:10.1074/jbc.M209706200.
   PubMed Web of Science ®Google Scholar
• Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(10):6251–6261. doi:10.4049/jimmunol.0803978.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–3925. doi:10.1073/pnas.0509592103.
   PubMed Web of Science ®Google Scholar
• Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C, et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature. 2020;577(7790):410–415. doi:10.1038/s41586-019-1865-0.
   PubMed Web of Science ®Google Scholar
• Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, Matsuoka K, et al. TGR 5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology. 2013;139(1):19–29. doi:10.1111/imm.12045.
   PubMed Web of Science ®Google Scholar
• Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, Mai C, Jin W-B, Guo C-J, Violante S, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature. 2020;581(7809):475–479. doi:10.1038/s41586-020-2193-0.
   PubMed Web of Science ®Google Scholar
• Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576(7785):143–148. doi:10.1038/s41586-019-1785-z.
   PubMed Web of Science ®Google Scholar
• Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, Monma T, Konishi N, Yara S, Hirayama T, et al. Detection of gut dysbiosis due to reduced Clostridium Subcluster XIVa using the fecal or serum bile acid profile. Inflamm Bowel Dis. 2018;24(5):1035–1044. doi:10.1093/ibd/izy022.
   PubMed Web of Science ®Google Scholar
• Bamba S, Inatomi O, Nishida A, Ohno M, Imai T, Takahashi K, Naito Y, Iwamoto J, Honda A, Inohara N, et al. Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease. Intest Res. 2022;20(3):370–380. doi:10.5217/ir.2021.00054.
   PubMed Web of Science ®Google Scholar
• Hu J, Wang C, Huang X, Yi S, Pan S, Zhang Y, Yuan G, Cao Q, Ye X, Li H, et al. Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. Cell Rep. 2021;36(12):109726. doi:10.1016/j.celrep.2021.109726.
   PubMed Web of Science ®Google Scholar
• Torres J, Palmela C, Brito H, Bao X, Ruiqi H, Moura-Santos P, Pereira da Silva J, Oliveira A, Vieira C, Perez K, et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United Eur Gastroenterol J. 2018;6(1):112–122. doi:10.1177/2050640617708953.
   PubMed Web of Science ®Google Scholar
• Rühlemann M, Liwinski T, Heinsen FA, Bang C, Zenouzi R, Kummen M, Thingholm L, Tempel M, Lieb W, Karlsen T, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019;50(5):580–589. doi:10.1111/apt.15375.
   PubMed Web of Science ®Google Scholar
• Yang R, Yu W, Lin L, Jin M, Hu S, Jiang B, Mao C, Li G, Tang J, Gu Y, et al. Profiling of bile acids and activated receptor S1PR2 in gingival tissues of periodontitis patients. J Periodontol. 2023;94(4):564–574. doi:10.1002/JPER.22-0398.
   PubMed Web of Science ®Google Scholar
• Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, Maruya M, Ian McKenzie C, Hijikata A, Wong C, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun. 2015;6(1):6734. doi:10.1038/ncomms7734.
   PubMed Web of Science ®Google Scholar
• Gaudier E, Jarry A, Blottière HM, de Coppet P, Buisine MP, Aubert JP, Laboisse C, Cherbut C, Hoebler C. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol. 2004;287(6):G1168–74. doi:10.1152/ajpgi.00219.2004.
   PubMed Web of Science ®Google Scholar
• Nakamura YK, Janowitz C, Metea C, Asquith M, Karstens L, Rosenbaum JT, Lin P. Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine. Sci Rep. 2017;7(1):11745. doi:10.1038/s41598-017-12163-3.
   PubMedGoogle Scholar
• Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol Immunol. 2021;18(4):866–877. doi:10.1038/s41423-021-00661-4.
   PubMed Web of Science ®Google Scholar
• Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroentero. 2020;26(21):2768–2780. doi:10.3748/wjg.v26.i21.2768.
   PubMed Web of Science ®Google Scholar
• Rosser EC, Piper CJM, Matei DE, Blair PA, Rendeiro AF, Orford M, Alber DG, Krausgruber T, Catalan D, Klein N, et al. Microbiota-derived metabolites suppress arthritis by amplifying Aryl-Hydrocarbon receptor activation in regulatory B cells. Cell Metab. 2020;31(4):837–51.e10. doi:10.1016/j.cmet.2020.03.003.
   PubMed Web of Science ®Google Scholar
• Bungau SG, Behl T, Singh A, Sehgal A, Singh S, Chigurupati S, Vijayabalan S, Das S, Palanimuthu VR. Targeting probiotics in rheumatoid arthritis. Nutrients. 2021;13(10):3376. doi:10.3390/nu13103376.
   PubMed Web of Science ®Google Scholar
• Eryavuz OD, Sivrikaya A, Isik K, Abusoglu S, Albayrak GI, Humeyra YF, Abusoglu G, Unlu A, Tezcan D. Altered kynurenine pathway metabolism in patients with ankylosing spondylitis. Int Immunopharmacol. 2021;99:108018. doi:10.1016/j.intimp.2021.108018.
   PubMed Web of Science ®Google Scholar
• Harden JL, Lewis SM, Lish SR, Suárez-Fariñas M, Gareau D, Lentini T, Johnson-Huang LM, Krueger JG, Lowes MA. The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. J Allergy Clin Immunol. 2016;137(6):1830–1840. doi:10.1016/j.jaci.2015.09.055.
   PubMed Web of Science ®Google Scholar
• Muñiz DA, Chen J, Hillmann B, Jeraldo P, Al-Ghalith G, Taneja V, Davis JM, Knights D, Nelson H, Faubion WA, et al. An increased abundance of clostridiaceae characterizes arthritis in inflammatory bowel disease and rheumatoid arthritis: a cross-sectional study. Inflamm Bowel Dis. 2019;25(5):902–913. doi:10.1093/ibd/izy318.
   PubMed Web of Science ®Google Scholar
• Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67(1):128–139. doi:10.1002/art.38892.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Masuoka N, Kano M, Iizuka R. Bifidobacterium fermented milk and galacto-oligosaccharides lead to improved skin health by decreasing phenols production by gut microbiota. Benef Microbes. 2014;5(2):121–128. doi:10.3920/BM2012.0066.
   PubMed Web of Science ®Google Scholar
• Sikora M, Stec A, Chrabaszcz M, Giebultowicz J, Samborowska E, Jazwiec R, Dadlez M, Olszewska M, Rudnicka L. Clinical implications of intestinal barrier damage in psoriasis. J Inflamm Res. 2021;14:237–243. doi:10.2147/JIR.S292544.
   PubMed Web of Science ®Google Scholar
• Wu K, Yuan Y, Yu H, Dai X, Wang S, Sun Z, Wang F, Fei H, Lin Q, Jiang H, et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood. 2020;136(4):501–515. doi:10.1182/blood.2019003990.
   PubMed Web of Science ®Google Scholar
• Kummen M, Thingholm LB, Rühlemann MC, Holm K, Hansen SH, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, et al. Altered gut microbial metabolism of essential Nutrients in primary sclerosing cholangitis. Gastroenterology. 2021;160(5):1784–98.e0. doi:10.1053/j.gastro.2020.12.058.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. The Lancet. 2012;380(9853):1590–1605. doi:10.1016/S0140-6736(12)60026-9.
   PubMed Web of Science ®Google Scholar
• Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145(1):16–27. doi:10.1016/j.jaci.2019.11.003.
   PubMed Web of Science ®Google Scholar
• De Francesco MA, Caruso A. The gut microbiome in psoriasis and Crohn’s disease: Is its perturbation a common denominator for their pathogenesis? Vaccines (Basel). 2022;10(2):10. doi:10.3390/vaccines10020244.
   Web of Science ®Google Scholar
• Kabeerdoss J, Sandhya P, Danda D. Gut inflammation and microbiome in spondyloarthritis. Rheumatol Int. 2016;36(4):457–468. doi:10.1007/s00296-015-3414-y.
   PubMed Web of Science ®Google Scholar
• Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, Kikly K, Wang R, Tseng H-W, Thomas GP, et al. Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66(7):1755–1767. doi:10.1002/art.38638.
   PubMed Web of Science ®Google Scholar
• Liu X, Zeng B, Zhang J, Li W, Mou F, Wang H, Zou Q, Zhong B, Wu L, Wei H, et al. Role of the gut microbiome in modulating arthritis progression in mice. Sci Rep. 2016;6(1):30594. doi:10.1038/srep30594.
   PubMedGoogle Scholar
• Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–827. doi:10.1016/j.immuni.2010.06.001.
   PubMed Web of Science ®Google Scholar
• Teng F, Klinger CN, Felix KM, Bradley CP, Wu E, Tran NL, Umesaki Y, Wu H-J. Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of Peyer’s Patch T follicular helper cells. Immunity. 2016;44(4):875–888. doi:10.1016/j.immuni.2016.03.013.
   PubMed Web of Science ®Google Scholar
• Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A, et al. IgA-coated E. coli enriched in Crohn’s disease spondyloarthritis promote TH 17-dependent inflammation. Sci Transl Med. 2017;9(376):eaaf9655. doi:10.1126/scitranslmed.aaf9655.
   PubMed Web of Science ®Google Scholar
• Sun H, Guo Y, Wang H, Yin A, Hu J, Yuan T, Zhou S, Xu W, Wei P, Yin S, et al. Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis. Gut. 2023;72(9):1664–1677. doi:10.1136/gutjnl-2022-327756.
   PubMed Web of Science ®Google Scholar
• Jiang L, Shang M, Yu S, Liu Y, Zhang H, Zhou Y, Wang M, Wang T, Li H, Liu Z, et al. A high-fiber diet synergizes with Prevotella copri and exacerbates rheumatoid arthritis. Cell Mol Immunol. 2022;19(12):1414–1424. doi:10.1038/s41423-022-00934-6.
   PubMed Web of Science ®Google Scholar
• Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol. 2008;1(5):364–371. doi:10.1038/mi.2008.24.
   PubMed Web of Science ®Google Scholar
• Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Am J Gastroenterol. 2020;115(6):814–822. doi:10.14309/ajg.0000000000000604.
   PubMed Web of Science ®Google Scholar
• Mathies F, Steffens N, Kleinschmidt D, Stuhlmann F, Huber FJ, Roy U, Meyer T, Luetgehetmann M, von Petersdorff M, Seiz O, et al. Colitis promotes a pathological condition of the liver in the absence of Foxp3(+) regulatory T cells. J Immunol. 2018;201(12):3558–3568. doi:10.4049/jimmunol.1800711.
   PubMed Web of Science ®Google Scholar
• Nagao JI, Kishikawa S, Tanaka H, Toyonaga K, Narita Y, Negoro-Yasumatsu K, Tasaki S, Arita-Morioka K-I, Nakayama J, Tanaka Y, et al. Pathobiont-responsive Th17 cells in gut-mouth axis provoke inflammatory oral disease and are modulated by intestinal microbiome. Cell Rep. 2022;40(10):111314. doi:10.1016/j.celrep.2022.111314.
   PubMed Web of Science ®Google Scholar
• Noto LM, Sarnacki SH, Aya CMR, Bernal MI, Giacomodonato MN, Cerquetti MC. Consumption of Lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expression. PloS One. 2013;8(12):e82588. doi:10.1371/journal.pone.0082588.
   PubMed Web of Science ®Google Scholar
• Fan Z, Ross RP, Stanton C, Hou B, Zhao J, Zhang H, Yang B, Chen W. Lactobacillus casei CCFM1074 alleviates collagen-induced arthritis in rats via balancing Treg/Th17 and modulating the metabolites and gut microbiota. Front Immunol. 2021;12:680073. doi:10.3389/fimmu.2021.680073.
   PubMed Web of Science ®Google Scholar
• Marietta EV, Murray JA, Luckey DH, Jeraldo PR, Lamba A, Patel R, Luthra HS, Mangalam A, Taneja V. Suppression of inflammatory arthritis by human gut-derived Prevotella histicola in humanized mice. Arthritis Rheumatol. 2016;68(12):2878–2888. doi:10.1002/art.39785.
   PubMed Web of Science ®Google Scholar
• Sanges M, Valente G, Rea M, Della GR, De Franchis G, Sollazzo R, D’Arienzo A. Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci. 2009;13:233–234.
   PubMed Web of Science ®Google Scholar
• Chen YH, Wu CS, Chao YH, Lin CC, Tsai HY, Li YR, Chen Y-Z, Tsai W-H, Chen Y-K. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J Food Drug Anal. 2017;25(3):559–566. doi:10.1016/j.jfda.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EMM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–339. doi:10.4161/gmic.25487.
   PubMed Web of Science ®Google Scholar
• Navarro-López V, Martínez-Andrés A, Ramírez-Boscá A, Ruzafa-Costas B, Núñez-Delegido E, Carrión-Gutiérrez MA, Prieto-Merino D, Codoñer-Cortés F, Ramón-Vidal D, Genovés-Martínez S, et al. Efficacy and safety of oral administration of a mixture of probiotic Strains in patients with psoriasis: a randomized controlled clinical trial. Acta Derm Venereol. 2019;99:1078–1084. doi:10.2340/00015555-3305.
   PubMed Web of Science ®Google Scholar
• Dusek O, Fajstova A, Klimova A, Svozilkova P, Hrncir T, Kverka M, Coufal S, Slemin J, Tlaskalova-Hogenova H, Forrester JV, et al. Severity of experimental autoimmune uveitis is reduced by pretreatment with live probiotic Escherichia coli Nissle 1917. Cells. 2020;10(1):10. doi:10.3390/cells10010023.
   PubMed Web of Science ®Google Scholar
• Kim J, Choi SH, Kim YJ, Jeong HJ, Ryu JS, Lee HJ, Kim T, Im S-H, Oh J, Kim M, et al. Clinical effect of IRT-5 probiotics on immune Modulation of Autoimmunity or Alloimmunity in the Eye. Nutrients. 2017;9(11):1166. doi:10.3390/nu9111166.
   PubMed Web of Science ®Google Scholar
• Invernici MM, Salvador SL, Silva PHF, Soares MSM, Casarin R, Palioto DB, Souza SLS, Taba M, Novaes AB, Furlaneto FAC, et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: A randomized clinical trial. J Clin Periodontol. 2018;45(10):1198–1210. doi:10.1111/jcpe.12995.
   PubMed Web of Science ®Google Scholar
• Tekce M, Ince G, Gursoy H, Dirikan Ipci S, Cakar G, Kadir T, Yılmaz S. Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study. J Clin Periodontol. 2015;42(4):363–372. doi:10.1111/jcpe.12387.
   PubMed Web of Science ®Google Scholar
• Hoentjen F, Welling GW, Harmsen HJ, Zhang X, Snart J, Tannock GW, Lien K, Churchill TA, Lupicki M, Dieleman LA, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis. 2005;11(11):977–985. doi:10.1097/01.MIB.0000183421.02316.d5.
   PubMed Web of Science ®Google Scholar
• Levi Y, Novais GS, Dias RB, Andraus RAC, Messora MR, Neto HB, Ervolino E, Santinoni CS, Maia LP. Effects of the prebiotic mannan oligosaccharide on the experimental periodontitis in rats. J Clin Periodontol. 2018;45(9):1078–1089. doi:10.1111/jcpe.12987.
   PubMed Web of Science ®Google Scholar
• Li ZY, Zhou JJ, Luo CL, Zhang LM. Activation of TGR5 alleviates inflammation in rheumatoid arthritis peripheral blood mononuclear cells and in mice with collagen II‑induced arthritis. Mol Med Rep. 2019;20(5):4540–4550. doi:10.3892/mmr.2019.10711.
   PubMed Web of Science ®Google Scholar
• Hasan H, Ismail H, El-Orfali Y, Khawaja G. Therapeutic benefits of indole-3-Carbinol in adjuvant-induced arthritis and its protective effect against methotrexate induced-hepatic toxicity. BMC Complement Altern Med. 2018;18(1):337. doi:10.1186/s12906-018-2408-1.
   PubMed Web of Science ®Google Scholar
• Ebringer A, Wilson C. The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. Clin Rheumatol. 1996;15(Suppl 1):62–66. doi:10.1007/BF03342649.
   PubMedGoogle Scholar
• Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549–558. doi:10.1016/j.jhep.2017.05.009.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73(1):94–101. doi:10.1016/j.jhep.2020.02.033.
   PubMed Web of Science ®Google Scholar
• Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, et al. The nonsteroidal farnesoid X receptor Agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatol. 2019;70(3):788–801. doi:10.1002/hep.30509.
   PubMed Web of Science ®Google Scholar
• Wu Z, Liu X, Huang S, Li T, Zhang X, Pang J, Zhao J, Chen L, Zhang B, Wang J, et al. Milk fat globule membrane attenuates acute colitis and secondary liver injury by improving the mucus barrier and regulating the gut microbiota. Front Immunol. 2022;13:865273. doi:10.3389/fimmu.2022.865273.
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Maeda K, Hidaka K, Nemoto K, Hirose Y, Deguchi S. Daily Intake of heat-killed Lactobacillus plantarum L-137 decreases the probing depth in patients undergoing supportive periodontal therapy. Oral Health Prev Dent. 2016;14(3):207–214. doi:10.3290/j.ohpd.a36099.
   PubMed Web of Science ®Google Scholar
• Tabuchi Y, Katsushima M, Nishida Y, Shirakashi M, Tsuji H, Onizawa H, Kitagori K, Akizuki S, Nakashima R, Murakami K, et al. Oral dextran sulfate sodium administration induces peripheral spondyloarthritis features in SKG mice accompanied by intestinal bacterial translocation and systemic Th1 and Th17 cell activation. Arthritis Res Ther. 2022;24(1):176. doi:10.1186/s13075-022-02844-4.
   PubMed Web of Science ®Google Scholar
• Nakamura YK, Metea C, Karstens L, Asquith M, Gruner H, Moscibrocki C, Lee I, Brislawn CJ, Jansson JK, Rosenbaum JT, et al. Gut microbial Alterations associated with Protection from autoimmune uveitis. Invest Ophthalmol Visual Sci. 2016;57(8):3747–3758. doi:10.1167/iovs.16-19733.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37(6):604–612. doi:10.1111/apt.12232.
   PubMed Web of Science ®Google Scholar
• Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointestin Liver Dis. 2016;25(4):457–464. doi:10.15403/jgld.2014.1121.254.rah.
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Kärkkäinen P. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatol. 2004;40(6):1379–1386. doi:10.1002/hep.20457.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2009;104(1):83–88. doi:10.1038/ajg.2008.14.
   PubMed Web of Science ®Google Scholar
• Shah A, Crawford D, Burger D, Martin N, Walker M, Talley NJ, Tallis C, Jones M, Stuart K, Keely S, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis. 2019;39(4):432–441. doi:10.1055/s-0039-1688501.
   PubMed Web of Science ®Google Scholar
• Teughels W, Feres M, Oud V, Martín C, Matesanz P, Herrera D. Adjunctive effect of systemic antimicrobials in periodontitis therapy: a systematic review and meta-analysis. J Clinic Periodontology. 2020;47(Suppl S22):257–281. doi:10.1111/jcpe.13264.
   PubMedGoogle Scholar
• Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, Smith M, Gerardin Y, Timberlake S, Pratt DS, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114(7):1071–1079. doi:10.14309/ajg.0000000000000115.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastro Hepat. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Y, Stanton C, Ross RP, Zhao J, Chen W, Yang B. Dose–response efficacy and mechanisms of orally administered Bifidobacterium breve CCFM683 on IMQ-Induced psoriasis in mice. Nutrients. 2023;15(8):15. doi:10.3390/nu15081952.
   Web of Science ®Google Scholar
• Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, et al. Expert consensus document: The International Scientific Association for probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastro Hepat. 2017;14(8):491–502. doi:10.1038/nrgastro.2017.75.
   PubMed Web of Science ®Google Scholar
• Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastro Hepat. 2021;18(9):649–667. doi:10.1038/s41575-021-00440-6.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D, et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019;156(5):1440–54.e2. doi:10.1053/j.gastro.2018.12.001.
   PubMed Web of Science ®Google Scholar